References of "Legrand, Catherine"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailGlycation marker glucosepane increases with the progression of osteoarthritis and correlates with morphological and functional changes of cartilage in vivo
Legrand, Catherine; Ahmed, U.; Anwar, A. et al

in Arthritis Research and Therapy (2018), 20(1), 131

Background: Changes of serum concentrations of glycated, oxidized, and nitrated amino acids and hydroxyproline and anticyclic citrullinated peptide antibody status combined by machine learning techniques ... [more ▼]

Background: Changes of serum concentrations of glycated, oxidized, and nitrated amino acids and hydroxyproline and anticyclic citrullinated peptide antibody status combined by machine learning techniques in algorithms have recently been found to provide improved diagnosis and typing of early-stage arthritis of the knee, including osteoarthritis (OA), in patients. The association of glycated, oxidized, and nitrated amino acids released from the joint with development and progression of knee OA is unknown. We studied this in an OA animal model as well as interleukin-1β-activated human chondrocytes in vitro and translated key findings to patients with OA. Methods: Sixty male 3-week-old Dunkin-Hartley guinea pigs were studied. Separate groups of 12 animals were killed at age 4, 12, 20, 28 and 36 weeks, and histological severity of knee OA was evaluated, and cartilage rheological properties were assessed. Human chondrocytes cultured in multilayers were treated for 10 days with interleukin-1β. Human patients with early and advanced OA and healthy controls were recruited, blood samples were collected, and serum or plasma was prepared. Serum, plasma, and culture medium were analyzed for glycated, oxidized, and nitrated amino acids. Results: Severity of OA increased progressively in guinea pigs with age. Glycated, oxidized, and nitrated amino acids were increased markedly at week 36, with glucosepane and dityrosine increasing progressively from weeks 20 and 28, respectively. Glucosepane correlated positively with OA histological severity (r = 0.58, p < 0.0001) and instantaneous modulus (r = 0.52-0.56; p < 0.0001), oxidation free adducts correlated positively with OA severity (p < 0.0009-0.0062), and hydroxyproline correlated positively with cartilage thickness (p < 0.0003-0.003). Interleukin-1β increased the release of glycated and nitrated amino acids from chondrocytes in vitro. In clinical translation, plasma glucosepane was increased 38% in early-stage OA (p < 0.05) and sixfold in patients with advanced OA (p < 0.001) compared with healthy controls. Conclusions: These studies further advance the prospective role of glycated, oxidized, and nitrated amino acids as serum biomarkers in diagnostic algorithms for early-stage detection of OA and other arthritic disease. Plasma glucosepane, reported here for the first time to our knowledge, may improve early-stage diagnosis and progression of clinical OA. © 2018 The Author(s). [less ▲]

Detailed reference viewed: 29 (3 ULiège)
Full Text
Peer Reviewed
See detailUse of the Beta-Binomial Model for Central Statistical Monitoring of Multicenter Clinical Trials
Desmet, L.; Venet, D.; Doffagne, E. et al

in Statistics in Biopharmaceutical Research (2017), 9(1), 1-11

As part of central statistical monitoring of multicenter clinical trial data, we propose a procedure based on the beta-binomial distribution for the detection of centers with atypical values for the ... [more ▼]

As part of central statistical monitoring of multicenter clinical trial data, we propose a procedure based on the beta-binomial distribution for the detection of centers with atypical values for the probability of some event. The procedure makes no assumptions about the typical event proportion and uses the event counts from all centers to derive a reference model. The procedure is shown through simulations to have high sensitivity and high specificity if the contamination rate is small and the atypical event proportions are the result of some systematic shift in the underlying data-generating mechanism. © 2017 American Statistical Association. [less ▲]

Detailed reference viewed: 24 (3 ULiège)
Full Text
Peer Reviewed
See detailLe glucosépane : un nouveau marqueur de la sévérité de l’arthrose
Lambert, Cécile ULiege; Legrand, Catherine; Ahmed, Usman et al

in Revue du Rhumatisme (2017), 84S

Detailed reference viewed: 22 (4 ULiège)
Full Text
Peer Reviewed
See detailStatistical monitoring of data quality and consistency in the Stomach Cancer Adjuvant Multi-institutional Trial Group Trial
Timmermans, Catherine ULiege; Doffagne, Erik; Venet, David et al

in Gastric Cancer (2016), 19(1), 24-30

Data quality may impact the outcome of clinical trials; hence, there is a need to implement quality control strategies for the data collected. Traditional approaches to quality control have primarily used ... [more ▼]

Data quality may impact the outcome of clinical trials; hence, there is a need to implement quality control strategies for the data collected. Traditional approaches to quality control have primarily used source data verification during on-site monitoring visits, but these approaches are hugely expensive as well as ineffective. There is growing interest in central statistical monitoring (CSM) as an effective way to ensure data quality and consistency in multicenter clinical trials. [less ▲]

Detailed reference viewed: 33 (3 ULiège)
Peer Reviewed
See detailLes objectifs de la formation des soignants en Education Thérapeutique du Patient : une proposition
Pétré, Benoît ULiege; Guillaume, Michèle ULiege; LEGRAND, Catherine et al

Conference (2014, September)

Detailed reference viewed: 70 (13 ULiège)
Full Text
Peer Reviewed
See detailLinear mixed-effects models for central statistical monitoring of multicenter clinical trials.
Desmet, Lieven; Venet, D.; Doffagne, E. et al

in Statistics in Medicine (2014), 33(30), 5265-5279

Multicenter studies are widely used to meet accrual targets in clinical trials. Clinical data monitoring is required to ensure the quality and validity of the data gathered across centers. One approach to ... [more ▼]

Multicenter studies are widely used to meet accrual targets in clinical trials. Clinical data monitoring is required to ensure the quality and validity of the data gathered across centers. One approach to this end is central statistical monitoring, which aims at detecting atypical patterns in the data by means of statistical methods. In this context, we consider the simple case of a continuous variable, and we propose a detection procedure based on a linear mixed-effects model to detect location differences between each center and all other centers. We describe the performance of the procedure as a function of contamination rate and signal-to-noise ratio. We investigate the effect of center size and variance structure and illustrate the use of the procedure using data from two multicenter clinical trials. Copyright © 2014 John Wiley & Sons, Ltd. [less ▲]

Detailed reference viewed: 22 (2 ULiège)
Full Text
Peer Reviewed
See detailLikelihood based inference for semi-competing risks
Heuchenne, Cédric ULiege; Laurent, Stéphane ULiege; Legrand, Catherine et al

in Communications in Statistics: Simulation and Computation (2014), 43(5), 1112-1132

Detailed reference viewed: 83 (11 ULiège)
Full Text
Peer Reviewed
See detailSoluble Mesothelin, Megakaryocyte Potentiating Factor and Osteopontin as Markers of Patient Response and Outcome in Mesothelioma
Hollevoet, Kevin; Nackaerts, Kristiaan; Gosselin, Robert et al

in Journal of Thoracic Oncology (2011), 6(11), 1930-1937

Detailed reference viewed: 35 (4 ULiège)
See detailLikelihood based inference for semi-competing risks
Heuchenne, Cédric ULiege; Legrand, Catherine; Laurent, Stéphane ULiege et al

E-print/Working paper (2011)

Detailed reference viewed: 39 (4 ULiège)
Full Text
Peer Reviewed
See detailA Bayesian framework for the ratio of two Poisson rates in the context of vaccine efficacy trials
Laurent, Stéphane ULiege; Legrand, Catherine

in ESAIM: Probability and Statistics (2011)

In many applications, we assume that two random observations x and y are generated according to independent Poisson distributions and we are interested in performing statistical inference on the ratio of ... [more ▼]

In many applications, we assume that two random observations x and y are generated according to independent Poisson distributions and we are interested in performing statistical inference on the ratio of the two incidence rates, called the relative risk in vaccine efficacy trials, in which context x and y are the numbers of cases in the vaccine and the control groups respectively. In this paper we start by defining a natural semi-conjugate family of prior distributions for this model, allowing straightforward computation of the posterior inference. Following theory on reference priors, we define the reference prior for the partial immunity model when the relative risk is the parameter of interest. We also define a family of reference priors with partial information on the incidence rate of the unvaccinated population while remaining uninformative about the relative risk . We notice that these priors belong to the semi-conjugate family. We then demonstrate using numerical examples that Bayesian credible intervals enjoy attractive frequentist properties when using reference priors, a typical property of reference priors. [less ▲]

Detailed reference viewed: 174 (27 ULiège)
Full Text
Peer Reviewed
See detailDiagnostic Performance of Soluble Mesothelin and Megakaryocyte Potentiating Factor in Mesothelioma
Hollevoet, Kevin; Thimpont, Joël; Germonpré, Paul et al

in American Journal of Respiratory and Critical Care Medicine (2010), 181

Detailed reference viewed: 17 (1 ULiège)
Full Text
Peer Reviewed
See detailA phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956)
Scagliotti, G. V.; Smit, E.; Bosquee, Léon ULiege et al

in Lung Cancer (2005), 50(1), 91-96

Purpose: The incidence of bronchioloalveolar carcinoma (BAC) has risen steadily over the last decades along with the increasing frequency of adenocarcinomas. BAC is relatively resistant to commonly used ... [more ▼]

Purpose: The incidence of bronchioloalveolar carcinoma (BAC) has risen steadily over the last decades along with the increasing frequency of adenocarcinomas. BAC is relatively resistant to commonly used chemotherapy regimens. A phase 11 study with single agent pactitaxel in patients with stages IIIB, IV or recurrent BAC was performed. Experimental design: Patients with BAC with at least one target bidimensionally measurable lesion staged as unresectable stages IIIB, IV or recurrent disease, not previously irradiated; ECOG performance status 0-2; life expectancy greater than 3 months; age range between 18 and 75, received pactitaxel at a dose of 200 mg/m(2) i.v. as 3 h continuous infusion on day 1 every 21 days. Treatment was continued until progression or up to a maximum of six cycles. Results: Nineteen patients were eligible. Median number of cycles was 3 (range 0-6); 35% of patients received the planned six cycles of chemotherapy. One patient died of unrelated cause before the start of treatment. Both hematological and non-hematological toxicities were generally mild. Only one partial response (PR) was observed among the 18 eligible patients who started protocol treatment, with a response rate of 5.6% (95% Cl: 0.1-27.3%). After an independent review, two PR were confirmed, for a response rate of 11.1% (95% CI: 1.4-34.7%); nine patients had stable disease (50.0%), three patients had progressive disease (11.1%) and four patients were not assessable (22.2%). Median survival was 8.6 months (95% CI: 5.8-14.5) and 1-year survival was 35.0% (95% CI: 14.1-55.8). Median progression free survival for all patients was 2.2 months (95% CI: 1.5-6.0). The study was terminated due to the low response rate. Conclusions: Pactitaxel as single agent in stages IIIB-IV BAC was well tolerated and manageable but of limited efficacy. BAC should not be excluded from trials of new forms of chemotherapy. (c) 2005 Elsevier Ireland Ltd. All rights reserved. [less ▲]

Detailed reference viewed: 58 (10 ULiège)
Full Text
Peer Reviewed
See detailEuropean Organization for Research and Treatment of Cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer
Ardizzoni, A.; Manegold, C.; Debruyne, C. et al

in Clinical Cancer Research (2003), 9(1), 143-150

Purpose: The purpose of this study was to assess the activity and toxicity of a combined regimen of topotecan and cisplatin in "sensitive" (s) and "refractory" (r) small-cell lung cancer (SCLC) patients ... [more ▼]

Purpose: The purpose of this study was to assess the activity and toxicity of a combined regimen of topotecan and cisplatin in "sensitive" (s) and "refractory" (r) small-cell lung cancer (SCLC) patients treated previously. Experimental Design: Patients with measurable SCLC and progressive disease after one first-line regimen were eligible for the study. Patients were enrolled in two separate groups: r group (patients who failed first-line treatment <3 months from treatment discontinuation) and s group (patients who responded to first-line treatment and progressed 2:3 months after treatment discontinuation). Cisplatin was given i.v. at the dose of 60 mg/m(2) on day 1, and topotecan was administered as a daily i.v. infusion at the dose of 0.75 mg/m(2) from day 1 to 5, every 3 weeks. Results: A total of 110 eligible (68 s and 42 r) patients were enrolled from 24 institutions. The main patient characteristics were as follows: median age 60 (s) and 55 (r) years, median performance status 1 for both (s) and (r). Seventy-four percent (s) and 67% (r) had extensive stage disease, including 22% and 36%, respectively, with brain metastases. A total of 398 chemotherapy courses were administered [median 4 (s) and 3 (r) per patient]. The most frequent and serious toxicity was myelosuppression. Grade IV neutropenia occurred in 62% (s) and 49% (r) of patients, with a 19% (s) and 15% (r) incidence of febrile neutropenia, and grade IV thrombocytopenia in 54% (s) and 44% (r). Most of these toxicities occurred during the first chemotherapy course and led to topotecan dose reduction and/or delay in the following courses. Grade III-IV nonhematological toxicity was uncommon. Five deaths possibly related to toxicity occurred among s patients only. Objective responses have been documented in 20 s patients, 19 partial responses and 1 complete response, (29.4% response rate; 95% confidence interval, 19-42), whereas, among r patients, 10 partial responses have been observed (23.8% response rate; 95% confidence interval, 12-39). Median survival for s and r was 6.4 and 6.1 months, respectively. Conclusions: The combination of cisplatin and topotecan, at this dose and schedule, shows activity and promising results in patients with refractory SCLC, with reversible myelosuppression being the main side effect. Additional development of this regimen, using better-tolerated schedules, is warranted in patients with refractory SCLC. [less ▲]

Detailed reference viewed: 39 (5 ULiège)